Analytical Data
-
Gene name
ppc
- Application
-
Alternative Names
ppc; glu; b3956; JW3928; Phosphoenolpyruvate carboxylase; PEPC; PEPCase; EC 4.1.1.31
-
Species
Escherichia coli
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P00864
-
Expression Region
5-883aa
-
Molecular Weight
102.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PPC (Prostatic Acid Phosphatase) recombinant protein research has gained significant attention due to its potential applications in cancer immunotherapy, particularly in prostate cancer. As a glycoprotein enzyme predominantly expressed in prostate tissue, PPC plays a role in phosphate metabolism and is also implicated in the tumor microenvironment. The isolation of recombinant PPC allows for a better understanding of its structural and functional properties. Moreover, it serves as a valuable tool for developing diagnostic and therapeutic strategies. With advancements in recombinant DNA technology, producing high-yield, active PPC has become feasible, enabling researchers to investigate its antigenic properties and potential use as a cancer biomarker. The focus on PPC also stems from its ability to elicit immune responses, providing a basis for its incorporation into vaccine formulations aimed at enhancing cytotoxic T-cell activity against prostate cancer cells. Thus, the study of PPC recombinant proteins is pivotal in exploring new avenues for early diagnosis and targeted therapies, contributing to improved patient outcomes in prostate cancer management.
